samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Luina Bio Announces New Bio-Manufacturing GMP And Development Facility Expansion

Luina Bio


1st September 2020

Highlights

• Small scale GMP manufacturing suites open in Q3 2020
• 500L tech transfer and process development site aim for open Q4 2020
• This precedes the next phase with Luina planning to commission a 10,000m2 late phase clinical and commercial production facility targeting late 2021
• New facilities capture more of the global value chain supporting technically advanced microbiome projects
• New expanded capacity for bacterial and yeast recombinant projects including vaccine manufacturing including COVID-19 candidates

Brisbane, Queensland – Luina Bio, one of Australia’s most experienced biopharmaceutical contract development and manufacturing (CDMO) organisations, is pleased to announce several expansion plans to meet the increasing demand in the microbiome and recombinant biopharma markets.

The first stage of the expansion will see Luina open additional small scale (30L) GMP manufacturing suite in late 2020, broadening he company’s service offering for new clinical projects that need small scale GMP facilities. This facility will be available to customers in Q3 2020 and has already generated interest from Luina Bio clients.

This will be followed by the opening of four additional development laboratories in late 2020, allowing Luina to take customer projects from the earliest development stage to a volume of 500L. This opening formally introduces the Company’s systems approach to facility design and utilisation, known as the Luina Flexible Manufacturing Platform (Luina FMP™). The Luina FMP™ environment is designed to deliver the speed and technical excellence necessary to handle the development of technically advanced microbiome & recombinant protein projects. It capitalises on years of experience Luina Bio has growing bacteria initially thought to be unable to be grown at useful quantities for customers.

Les Tillack, CEO of Luina Bio commented: “This new small-scale suite will allow us to respond to those customers that need a smaller active dose for their initial clinical development, while also giving them access to Luina’s proprietary FMP™ facility flexibility. Luina FMP™ was developed from over three decades of contract manufacturing experience, knowledge and expertise culminating in a unique manufacturing approach that advantages Luina Bio’s customers.”

New large-scale GMP Facility
Currently in planning, the next stage will see Luina develop a 10,000m2 late phase clinical and commercial production facility for commissioning in late 2021.

The new facility will have up to five production lines in parallel, ensuring that multiple-strain live biotherapeutics projects have compressed production times. Luina’s largest reactor (2,000L) will allow it to deliver live biotherapeutics volumes compatible with the commercial needs of those companies that have single-strain projects.

The facility will also boast new technologies to decrease the downstream processing time of live biotherapeutics and bacterial recombinant biotherapy projects dramatically.

“We aim to deliver the world’s most technologically advanced live biotherapeutics manufacturing plant so that our customers can be safe in the knowledge that their projects will be delivered on specification and on budget. This quality-centric approach will start at the earliest possible development stage and continue throughout the life of the project,” said Mr Tillack.

Over 200 companies and projects are exploring the potential of live biotherapeutic based medicines in a vast array of conditions. Luina Bio is at the forefront of this effort and intends to continue leading the global value chain in developing manufacturing solutions for our customers. It further expands Luina’s capability for expanded capacity for bacterial and yeast recombinant projects including vaccine manufacturing, particularly in light of COVID-19 vaccine manufacturing demand.

Mr Tillack further commented, “Luina Bio already possesses the intricate cGMP capabilities needed to manufacture a COVID-19 vaccine and has the potential to cut down the time associated with this type of infrastructure and advanced processes development by a number of years helping Australia’s preparedness for COVID and other potential pandemic challenges.

Luina Bio’s location allows it to use Australia’s high-quality scientific workforce for this expansion. Luina continues to work with the Queensland government grant programs enabling new process engineering, systems capability and jobs. The company will also be recruiting additional technical and scientific staff further supporting and growing the biotechnology industry in Queensland potentially up to a further 300 staff.

About Luina Bio

Luina Bio is one of Australia’s most experienced biopharmaceutical contract manufacturing organisations, offering a comprehensive set of services including cGMP manufacture in TGA/APVMA licensed facilities of recombinant proteins, vaccines, and synthetic molecules for human and veterinary uses. The company’s facilities have been in operation for over twenty years. For more information, please visit www.luinabio.com.au.

For further about Luina Bio information, please contact:
Les Tillack Luina Bio CEO
Phone: +61 7 3273 9176
phone +61 (07) 3273 9176
email enquiries@luinabio.com.au
web https://luinabio.com.au/
email 2806 Ipswich Road, Darra, QLD 4076, Australia
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Cobra Biologics completes production of Master Cell Banks for CombiGene’s epilepsy gene therapy drug candidate

Lund, Sweden and Keele, UK, 18 August 2020. Cobra Biologics (Cobra), part of the Cognate BioServices family, an international CDMO manufacturer of biological materials and pharmaceuticals, and CombiGene AB (publ) (CombiGene), the leading gene therapy company in the Nordic region, today announced that Cobra has successfully produced master cell banks for the three plasmids used as starting material for CombiGene’s gene therapy CG01. Critical to assuring ‘life time’ supply of therapeutic, this represents a further milestone in the future commercial manufacture of a drug candidate designed for the treatment of drug-resistant focal epilepsy.
More info >>


White Papers

The Rare Disease Patients Experience

When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
More info >>

Industry Events

DIA Europe 2021

15-19 March 2021, VIRTUAL CONFERENCE

DIA Europe is the must-attend event for all life science professionals working in drug development, from discovery to marketed use. It encourages open collaboration by bringing together representatives from the entire spectrum of the life science landscape and facilitating crucial discussions across several topic tracks: Clinical Development, Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy, and many more.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement